Exty develops AI-driven therapeutics focused on extending human lifespan and improving healthspan. The company leverages artificial intelligence to identify and create novel treatments aimed at enhancing biomarkers associated with longevity.
Funding
Funding not disclosed
Founders
Product
Problem
Developing therapeutics for age-related diseases is challenging due to the complexity of aging and the difficulty in identifying effective targets. Traditional drug discovery methods are often slow and inefficient in addressing the multifaceted nature of aging.
Solution
Exty is developing AI-driven therapeutics to extend human lifespan and improve healthspan by targeting key biomarkers associated with longevity. The company leverages artificial intelligence and machine learning to identify novel therapeutic targets and design molecules that can modulate these targets. By focusing on the underlying mechanisms of aging, Exty aims to create interventions that can prevent or delay the onset of age-related diseases and promote overall well-being.
Target Audience
The primary target audience includes individuals interested in longevity and healthspan, as well as pharmaceutical companies seeking innovative approaches to age-related diseases.
Features
- AI-driven drug discovery platform for identifying novel targets related to aging
- Machine learning models to predict the efficacy and safety of potential therapeutics
- Focus on enhancing biomarkers associated with longevity